NanoenTek,Inc.
Financials
Valuation Metrics
NanoenTek,Inc.'s Market Cap is ₩1710B. At end of 2025 it was ₩2286B. Ranked #901 of 2,405 in KR market (top 37%), #423 of 1,627 on KOSDAQ (top 26%), #104 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 171.04B KRW | KR#901/2,405 Sec#104/231 |
| Revenue | 44.19B KRW | KR#1,854/2,405 Sec#131/231 |
| Net Income | 5.86B KRW | KR#1,146/2,405 Sec#72/231 |
| Total Assets | 102.20B KRW | KR#1,756/2,405 Sec#140/231 |
| Net Assets | 94.06B KRW | KR#1,465/2,405 Sec#117/231 |
| Employees | 138 | KR#1,384/2,405 Sec#112/231 |
| Value | ||
| P/E | 29.18x | KR#1,316/2,405 Sec#82/231 |
| P/B | 1.82x | KR#1,920/2,405 Sec#141/231 |
| PEG | 0.13x | KR#478/2,405 Sec#25/231 |
| P/S | 3.87x | KR#2,088/2,405 Sec#133/231 |
| FCF Yield | 1.39% | KR#1,108/2,405 Sec#78/231 |
| Profitability | ||
| ROE | 6.23% | KR#963/2,405 Sec#68/231 |
| ROA | 5.74% | KR#658/2,405 Sec#54/231 |
| Op. Margin | 3.80% | KR#1,120/2,405 Sec#80/231 |
| Revenue Growth | 29.61% | KR#395/2,405 Sec#41/231 |
| Earnings Growth | 231.25% | KR#218/2,405 Sec#11/231 |
| Financial Health | ||
| Debt Ratio | 8.65% | KR#109/2,405 Sec#22/231 |
| FCF | 2.37B KRW | KR#1,056/2,405 Sec#74/231 |
| Cash | 12.26B KRW | KR#1,570/2,405 Sec#130/231 |
| Current Ratio | 11.28x | KR#81/2,405 Sec#20/231 |
| Performance | ||
| 1Y Return | 44.14% | KR#205/2,405 Sec#9/231 |
| 1M Return | -1.43% | KR#413/2,405 Sec#44/231 |
| From 52W High | -52.18% | KR#1,269/2,405 Sec#101/231 |
| 1Y MDD | -57.30% | KR#1,288/2,405 Sec#109/231 |
| Trading | ||
| Volume | 216,769 shares | KR#338/2,405 Sec#25/231 |
| Trading Value | 972.8M KRW | KR#595/2,405 Sec#63/231 |
| Foreign Own. | 1.36% | KR#1,876/2,405 Sec#185/231 |
| Per Share | ||
| EPS | 154 KRW | KR#1,354/2,405 Sec#90/231 |
| BPS | 2,469 KRW | KR#1,972/2,405 Sec#157/231 |
Company Info
NanoEnTek, established in 1987 as an information security business and rebranded in 2006, is headquartered in Guro-gu, Seoul. The company, slated to become a subsidiary of AAI Healthcare in 2025, specializes in Lab-on-a-chip based in-vitro diagnostic devices and immunodiagnostic systems. Its FREND System has received FDA approval and is stably supplied in North America. Utilizing Bio-MEMS and microfluidic technology, NanoEnTek conducts precise clinical tests, holding 108 registrations and expanding its business globally.